RNA Therapy Ulefnersen Shows First-Ever Survival Benefit in Phase 3 Trial for Fatal Genetic ALS
The targeted therapy ulefnersen significantly slowed disease progression and improved survival in patients with FUS-ALS, prompting developers to seek expedited regulatory approval.
By Maya Khalil
Share this story
The U.S. Food and Drug Administration and global health regulators will soon decide whether to approve the first targeted treatment for a rapid-onset, fatal form of amyotrophic lateral sclerosis (ALS). In the coming months, drugmakers Ionis Pharmaceuticals and Otsuka Pharmaceutical plan to submit data from a pivotal Phase 3 trial, asking agencies to grant expedited approval for their experimental RNA therapy, ulefnersen. If regulators clear the application, clinicians will have a disease-modifying intervention for a genetic condition that currently relies entirely on palliative care.[2][3]
The regulatory push follows the release of topline results from the FUSION trial, which tracked patients over a 72-week period. In a primary analysis of 73 participants, ulefnersen demonstrated a statistically significant improvement in a combined measure of physical function and survival compared to a placebo. The joint-rank analysis, measured from baseline to day 505, yielded a highly definitive efficacy signal (p=0.0005), confirming that the drug delayed the time until death or the need for permanent ventilation.[2][3][4]
Ulefnersen targets a specific genetic subtype known as FUS-ALS, caused by mutations in the fused in sarcoma (FUS) gene. While this variant accounts for only 0.6% of all ALS cases globally, it disproportionately strikes younger populations. According to Otsuka, FUS mutations drive an estimated 43% to 52% of pediatric and juvenile ALS cases, which typically progress much faster than adult-onset forms of the neurodegenerative disease.[2]
The therapy is an antisense oligonucleotide administered directly into the spinal fluid via an intrathecal injection. It works by binding to messenger RNA to block the production of the FUS protein, including the toxic mutant forms that cause motor neurons to rapidly degenerate. By halting this protein synthesis at the source, the drug preserves nerve function rather than merely managing the resulting symptoms.[4]
Beyond the primary clinical outcomes, blood tests from the trial confirmed the drug's biological mechanism. Patients receiving ulefnersen showed significant reductions in serum neurofilament light chain (NfL), a well-established biomarker that indicates active nerve cell damage. Lower NfL levels correlate directly with slowed neurodegeneration, providing regulators with objective biochemical evidence to support the clinical survival data.[2][3][4]
"Ulefnersen is the first investigational medicine to demonstrate a statistically significant benefit in a Phase 3 trial using a prespecified joint-rank analysis that combines assessments of function and survival," said Holly Kordasiewicz, chief development officer at Ionis. John Kraus, chief medical officer at Otsuka, noted that the data provides "compelling evidence that a targeted genetic approach may help alter the course of disease."[3][4][5]
For families facing a FUS-ALS diagnosis, the data offers a tangible shift in clinical management. However, ulefnersen is not a one-time cure; it requires ongoing spinal injections, and the trial reported mild to moderate adverse events associated with the treatment. Patients and caregivers will need to weigh the burden of repeated lumbar punctures against the proven survival benefits.[2][3]
While the FDA and the European Medicines Agency review the impending submissions, Otsuka has launched a global Early Access Program. This initiative allows eligible patients with confirmed FUS-ALS who cannot enroll in ongoing clinical trials to receive ulefnersen immediately. The commercial stakes are also solidifying; Otsuka previously paid Ionis $10 million upfront in 2024 to secure exclusive global rights to the therapy.[2][4]
Viewpoints in depth
Clinical Researchers
Focus on the validation of RNA-targeted therapies for neurodegeneration.
For neurologists and geneticists, the FUSION trial validates the antisense oligonucleotide approach for fatal brain diseases. Following the 2023 approval of Qalsody for SOD1-ALS, ulefnersen proves that targeting specific mRNA transcripts can successfully halt toxic protein production across different genetic variants. Researchers view the corresponding drop in neurofilament light chain (NfL) as critical proof that the biological mechanism translates directly into extended patient survival.
Patient Advocacy Groups
Emphasize the urgency of regulatory speed and expanded access.
ALS advocacy organizations stress that the rapid progression of FUS-ALS—particularly in children and young adults—leaves no time for standard regulatory timelines. They are heavily lobbying the FDA and global health authorities to utilize expedited review pathways. While welcoming Otsuka's Early Access Program, advocates argue that broad, insurance-covered commercial access must be authorized as quickly as possible to prevent further loss of life in the FUS-ALS community.
Key points
- Ulefnersen met its primary endpoint in the 73-patient Phase 3 FUSION trial.
- The RNA therapy significantly improved survival and physical function over 505 days compared to a placebo.
- FUS-ALS accounts for roughly half of all pediatric and juvenile ALS cases.
- Blood tests showed significant reductions in neurofilament light chain, a key marker of nerve damage.
How we got here
2019
The first patient receives the experimental therapy, then known as jacifusen, under compassionate use.
Nov 2024
Otsuka pays Ionis $10 million upfront for exclusive global rights to ulefnersen.
Sep 2026
Ionis and Otsuka announce the Phase 3 FUSION trial met its primary survival and function endpoints.
- Clinical Researchers
- Focus on the biological proof of concept and biomarker validation.
- Patient Advocacy Groups
- Focus on the urgency of expedited FDA review and expanded access.
Perspectives this story doesn't cover
- Health Insurance Payers
- Independent Health Economists
Sources
[1]EUpALSPatient Advocacy GroupsIonis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing treatment for FUS-ALS
Read on EUpALS →
[2]BioSpaceClinical ResearchersIonis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALS
Read on BioSpace →
[3]Drugs.comClinical ResearchersOtsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
Read on Drugs.com →
[4]ALS News TodayPatient Advocacy GroupsTargeted therapy may improve function, survival in FUS-ALS
Read on ALS News Today →
[5]NeurologyLiveClinical ResearchersUlefnersen Meets Primary End Point in Phase 3 FUSION Trial for FUS-ALS
Read on NeurologyLive →
More in Health
See all →Brain-Heart Axis
Brain-Heart Interaction Patterns Emerge as Prognostic Marker for Severe Oxygen Loss
5 sources
CTE Research
Blood Biomarker Shows Promise for Diagnosing Advanced CTE in Living Patients
3 sources
Liquid Biopsy
Novel Epigenetic Blood Test Detects Early Breast Cancer With 95 Percent Accuracy
5 sources
Brain Mapping
Molecular Map of 8 Million Brain Cells Unlocks Genetic Origins of Schizophrenia
6 sources
Comments
Every angle. Every day.
Get Health stories with full source coverage and perspective breakdowns, free every day.




